Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice

Journal of Experimental Medicine

Volumn 188, Issue 3, 1998, Pages 589-596

  Boggio, Katia ^a   Nicoletti, Giordano ^b   Di Carlo, Emma ^c   Cavallo, Federica ^a   Landuzzi, Lorena ^b   Melani, Cecilia ^d   Giovarelli, Mirella ^a   Rossi, Ilaria ^b   Nanni, Patrizia ^b   De Giovanni, Carla ^b   Bouchard, Page ^e   Wolf, Stanley ^e   Modesti, Andrea ^c   Musiani, Piero ^c   Lollini, Pier Luigi ^b   Colombo, Mario P ^d   Forni, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e PFIZER INC   (United States)

Author keywords

Adenocarcinomas; Angiogenesis; Her 2 neu; Interleukin 12; Tumor prevention

Indexed keywords

INTERLEUKIN 12; RECOMBINANT CYTOKINE;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GENETIC RISK; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CXC; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE DEPLETION; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RECEPTOR, ERBB-2; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0032479871     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.3.589     Document Type: Article

References (26)

1. Jonsen, R.A., S.J. Durfy, W. Burke, and A.G. Motulsky. 1996. The advent of the 'unpatient'. Nat. Med. 2:622-624.
2. Disis, M.L., and M.A. Cheever. 1996. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8:637-642.
3. Shih, C., L.C. Padhy, M. Murray, and R.A. Weinberger. 1981. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 290:261-264.
4. DiFiore, P.P., O. Segatto, W.G. Taylor, S.A. Aaronson, and J.H. Pierce. 1990. erb B-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 248:79-83.
5. Lucchini, F., M.G. Sacco, N. Hu, A. Villa, J. Brown, L. Cesano, L. Mangiarini, G. Rindi, S. Kindl, F. Sessa, et al. 1992. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett. 64:203-209.
6. Guy, C.T., M.A. Webster, M. Schaller, T.J. Parsons, R.D. Cardiff, and W. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89: 10578-10582.
7. Guy, C.T., R.D. Cardiff, and W.J. Muller. 1996. Activated neu induces rapid tumor progression. J. Biol. Chem. 271: 7673-7678.
8. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M.J. Brunda, M.P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049-1058.
9. Vecchi, A., C. Garlanda, M.G. Lampugnani, M. Resnati, C. Matteucci, A. Stoppacciaro, H. Schnurch, W. Risau, L. Ruco, and A. Mantovani. 1994. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur. J. Cell Biol. 63:247-254.
10. Giovarelli, M., A. Santoni, C. Jemma, T. Musso, A.M. Giuffrida, S. Landolfo, and G. Forni. 1988. Obligatory role of interferon-gamma in induction of lymphokine activated and T-lymphocyte killer activity, but not in boosting of natural cytotoxicity. J. Immunol. 141:2831-2836.
11. Stuehr, D.J., and C.F. Nathan. 1989. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169:1543-1555.
12. Wigginton, J.M., D.B. Kuhns, T.C. Back, M.J. Brunda, R.H. Wiltrout, and G.W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131-1136.
13. Sgadari, C., A.L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 87:3877-3882.
14. Liao, F., R.L. Rabin, J.R. Yannelli, L.G. Koniaris, P. Vanguri, and J.M. Farber. 1995. Human MIG chemokine: biochemical and functional characterization. J. Exp. Med. 182: 1301-1304.
15. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
16. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M.P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur. J. Immunol. 25:137-146.
17. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M.P. Colombo. 1996. IL-12 potentiates the curative effect of a vaccine based on IL-2 transduced tumor cells. Cancer Res. 56:467-470.
18. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
19. Voest, E.E., B.M. Kenyon, M.S. O'Reilly, G. Truitt, R.J. Truitt, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581-586.
20. Skobe, M., P. Rockwell, N. Goldstein, S. Vosseler, and N.E. Fusenig. 1997. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1222-1227.
21. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 338:59-61.
22. Tannenbaum, C.S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R.M. Bukowski, and T.A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:6933-6939.
23. Luster, A.D., and P. Leder. 1993. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057-1065.
24. Sgadari, C., J.M. Farber, A.L. Angiolillo, F. Liao, J. Teruya-Feldstein, P.R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. MIG, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood. 89:2635-2643.
25. Noguchi, Y., A. Jungblut, E.C. Richards, and L.L. Old. 1996. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA. 93:11798-11801.
26. Drebin, J.A., W.C. Link, R.A. Weinberg, and M.I. Greene 1996. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA. 83:9129-9133.